Research Article
Adverse Reaction Signals Mining of Vonoprazan: A Pharmacovigilance Study Based on FAERS
Table 4
Top significant signals on the PT level.
| | PT | ROR (95% CI) | IC (IC025) |
| | Plateletcrit increased | 1447.3 (265.05–7902.79) | 36.62 (6.71) | | Benign duodenal neoplasm | 1157.84 (224.6–5968.64) | 36.40 (7.06) | | Gallbladder volvulus | 964.77 (100.34–9276.00) | 36.20 (3.77) | | Myopathy endocrine | 723.58 (80.86–6474.59) | 35.88 (4.01) | | Pernio-like erythema | 723.58 (80.86–6474.59) | 35.88 (4.01) | | Septic coagulopathy | 723.58 (80.86–6474.59) | 35.88 (4.01) | | Hypergastrinaemia | 579.47 (311.69–1077.31) | 35.62 (19.16) | | Tertiary adrenal insufficiency | 482.39 (58.07–4007.30) | 35.40 (4.26) | | Luteinising hormone deficiency | 413.47 (50.87–3361.05) | 35.20 (4.33) | | Helicobacter sepsis | 361.79 (45.24–2892.99) | 35.03 (4.38) | | Hypoferritinaemia | 361.79 (45.24–2892.99) | 35.03 (4.38) | | Acrokeratosis paraneoplastica | 263.12 (33.97–2038.26) | 34.62 (4.47) | | Infected vasculitis | 263.12 (33.97–2038.26) | 34.62 (4.47) | | Antibiotic-associated colitis | 241.22 (57.00–1020.80) | 34.50 (8.15) | | HER2 positive gastric cancer | 231.57 (54.84–977.79) | 34.45 (8.16) | | Meningitis eosinophilic | 222.64 (29.12–1702.13) | 34.4 (04.50) | | Pulmonary artery wall hypertrophy | 222.64 (29.12–1702.13) | 34.40 (4.50) | | Atypical mycobacterial lymphadenitis | 206.74 (27.18–1572.35) | 34.30 (4.51) | | Rathke’s cleft cyst | 203.17 (73.70–560.04) | 34.27 (12.43) | | Duodenal polyp | 195.51 (106.14–360.14) | 34.22 (18.58) |
|
|
